« Back

Our Research

rheumatology research banner

  • Antiphospholipid Antibodies and Lupus: New Molecular Targets for Treatment, NIH-sponsored, 2013 - present
  • A Multicenter International Prospective, Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of Persistently Antiphospholipid Antibody (aPL) Positive but Thombosis-free Patients without Systemic Autoimmune Disease, 2013 - present
  • An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome, 2013 - present
  • A Phase IIb, Multi-Center, Randomized, Double-Blind,Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept (TACI-Ig) in Subjects With Systemic Lupus Erythematosus (SLE), 2014 - present.
  • "Treat-to-Target", a multi-center trial of RA, NIH-sponsored, out of Harvard university, Boston, under the leadership of Dr. Daniel Salomon, 2014 - present
  • Determination of cultured endothelial cells to examine the effects of various inhibitors that may block their binding and activation determine their thrombogenic effects in mice, 2007 - present
  • Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) International Clinical Database and Repository Collaborative Registry, 2013 - present

Elizabeth Papalardo Elizabeth Papalardo
Research Associate III
Division of Rheumatology
Department of Internal Medicine

Zurina Romay-Penabad Zurina Romay-Penabad, PhD
Post-Doctoral Fellow
Division of Rheumatology
Department of Internal Medicine

Alvaro Schleh Alvaro Schleh
Division of Rheumatology
Department of Internal Medicine

Rohan Willis Rohan Willis
Research Fellow
Division of Rheumatology
Department of Internal Medicine

The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.

Currently available protocols are:
  • CAP - Community Acquired Pneumonia Order set
  • Congestive Heart Failure (CHF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Diabetic Ketoacidosis Adult, ICU
  • General Medicine Admission
  • Immunodeficiency Flow Panel
  • MICU/CCU Admission Order Set
  • Oral Analgesic Medications
  • Parenteral Opioids
  • Sepsis, Adult ICU
  • 111 - Stroke Alert
  • 112 - Stroke Activation
  • 300086 - Stroke Floor Admission
  • 3000000001 -  Stroke Critical care without tPA
  • 300088 Stroke - Transfer from Critical care to floor
  • 3004002 - Stroke Discharge

All protocols can be found in the EPIC order set section.

» For more information

Meaning Use logo

The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.

Site Managed by UTMB Information Design Services.